Bisphosphonates Class Overview Monograph

Mechanism of Action and Pharmacology

Bisphosphonates act by binding to hydroxyapatite on bone surfaces undergoing active resorption, where osteoclasts internalize them during the resorption cycle. Once inside the osteoclast, nitrogen-containing bisphosphonates inhibit farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway [1]. This disrupts prenylation of small GTPases (Ras, Rho, Rac), which collapses the osteoclast cytoskeleton and triggers apoptosis [2].

Nitrogen-Containing vs. Non-Nitrogen Agents

All four clinically relevant oral and IV bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid) are nitrogen-containing. Older agents like etidronate and clodronate lack the nitrogen side chain, rely on cytotoxic ATP analog incorporation, and are rarely prescribed for osteoporosis today. The nitrogen-containing agents are 100 to 10,000 times more potent at FPPS inhibition than their predecessors [1].

Bone Binding and Skeletal Half-Life

Once deposited in bone matrix, bisphosphonates remain until that bone segment is remodeled. Alendronate's skeletal half-life exceeds 10 years [2]. This prolonged retention explains the residual anti-resorptive effect after discontinuation and forms the pharmacologic rationale for drug holidays. Zoledronic acid shows detectable urinary excretion up to 12 months after a single 5 mg infusion [3].

Oral Bioavailability Constraints

Oral bisphosphonates have exceptionally poor absorption. Bioavailability ranges from 0.6% (alendronate) to 1.5% (risedronate) under fasting conditions [4]. Co-ingestion with food, calcium, coffee, or juice can reduce absorption to near zero. This pharmacokinetic limitation drives the rigid dosing instructions: take on an empty stomach with 6 to 8 oz of plain water, remain upright, and wait 30 to 60 minutes before eating.

Agents, Formulations, and Dosing

Four bisphosphonates carry FDA approval for osteoporosis in the United States. Each differs in relative potency, route, and dosing interval.

Alendronate (Fosamax)

The prototype. Available as 70 mg weekly oral tablet, 10 mg daily tablet, and 70 mg effervescent tablet (Binosto). Generic 70 mg tablets cost under $10/month in most markets. The Fracture Intervention Trial (FIT; N=2,027) demonstrated a 47% reduction in spine fractures and a 51% reduction in hip fractures over 3 years [5].

Risedronate (Actonel)

Available as 35 mg weekly, 150 mg monthly, and delayed-release 35 mg weekly (Atelvia). Atelvia can be taken with food due to its enteric coating. The VERT-NA trial (N=2,458) showed a 41% reduction in new vertebral fractures at 3 years [6]. Risedronate has the fastest onset of fracture protection among oral agents, with vertebral fracture reduction apparent at 6 months.

Ibandronate (Boniva)

Available as 150 mg monthly oral or 3 mg quarterly IV. The BONE trial (N=2,946) showed 52% vertebral fracture reduction at 3 years [7]. A notable limitation: ibandronate has never demonstrated statistically significant hip fracture reduction in any randomized trial. The 2020 Endocrine Society guideline recommends against ibandronate when hip fracture risk is the primary concern [8].

Zoledronic Acid (Reclast)

The most potent agent. Given as 5 mg IV once yearly for osteoporosis. The HORIZON-PFT trial (N=7,765) demonstrated 70% reduction in vertebral fractures, 41% reduction in hip fractures, and 25% reduction in nonvertebral fractures at 3 years [3]. HORIZON-RFT (N=2,127) is the only osteoporosis trial to show a mortality benefit: 28% reduction in all-cause mortality after hip fracture when zoledronic acid was given within 90 days of fracture repair [9]. Annual IV dosing eliminates oral bioavailability issues and adherence problems tied to fasting protocols.

Clinical Efficacy: What the Key Trials Show

The evidence base for bisphosphonates in fracture prevention is among the deepest in osteoporosis pharmacotherapy, spanning over 30,000 patients across registrational trials.

Vertebral Fracture Data

All four agents reduce vertebral fractures by 40 to 70% over 3 years. The strongest effect belongs to zoledronic acid (70% RRR in HORIZON-PFT) [3]. Alendronate and risedronate cluster at 41 to 47% [5][6]. These reductions are consistent across subgroups defined by age, baseline T-score, and prevalent fracture status.

Hip and Nonvertebral Fracture Data

Only alendronate, risedronate, and zoledronic acid have demonstrated hip fracture efficacy. In a 2019 network meta-analysis published in the Journal of Bone and Mineral Research (N=43 trials, 138,523 participants), zoledronic acid ranked first for hip fracture prevention (OR 0.60, 95% CI 0.40 to 0.89) [10]. Ibandronate's absence of hip fracture data is not a class effect. It is a limitation specific to that molecule's trial design and lower binding affinity for cortical bone.

Glucocorticoid-Induced Osteoporosis

The 2017 American College of Rheumatology (ACR) guideline conditionally recommends oral bisphosphonates as initial therapy for adults aged 40 and older receiving prednisone 2.5 mg/day or more for 3 months or longer [11]. Alendronate and risedronate both have FDA approval for this indication. Zoledronic acid is preferred when adherence to oral therapy is uncertain or GI intolerance limits oral use.

Adverse Effects and Safety Signals

Bisphosphonates carry a favorable safety profile when used within guideline-recommended durations. Two rare but serious adverse effects dominate prescriber concern.

Upper GI Toxicity (Oral Agents)

Esophagitis, esophageal ulceration, and gastric erosion occur with oral formulations. Incidence in FIT was 24.5% for upper GI events in the alendronate group vs. 24.7% in placebo, suggesting that proper dosing technique minimizes excess risk [5]. The key instruction: swallow with a full glass of water, remain upright for 30 minutes (60 minutes for ibandronate), and do not lie down. Patients with active esophageal disorders (stricture, achalasia, Barrett esophagus) should not receive oral bisphosphonates.

Osteonecrosis of the Jaw (ONJ)

ONJ in the osteoporosis-dose setting is rare. A 2015 systematic review in the Journal of Dental Research estimated the incidence at 0.001 to 0.01% (1 in 10,000 to 1 in 100,000 patient-years) for oral bisphosphonates [12]. The risk is 50 to 100 times higher in oncology patients receiving high-dose IV zoledronic acid (4 mg monthly). The American Association of Oral and Maxillofacial Surgeons (AAOMS) 2022 position paper states: "For patients on oral antiresorptive therapy for osteoporosis, the risk of ONJ is very low, and withholding necessary dental procedures is not justified" [13].

Atypical Femoral Fractures (AFF)

AFF involves the subtrochanteric or diaphyseal femur, often bilateral, preceded by prodromal thigh pain. The 2020 ASBMR Task Force report estimated incidence at 3.2 to 50 per 100,000 person-years with bisphosphonate use, increasing with duration of therapy [14]. After 3 years of treatment the absolute risk is approximately 1 per 10,000 patient-years; after 8 or more years it may rise to 1 per 1,000 patient-years. This duration-dependent risk is the primary driver of drug holiday recommendations.

Acute Phase Reaction (IV Zoledronic Acid)

Fever, myalgia, and arthralgia occur in roughly 30% of patients after the first infusion of zoledronic acid, typically resolving within 72 hours [3]. Pre-treatment with acetaminophen 650 mg reduces severity. The incidence drops to under 7% with subsequent annual infusions.

Monitoring and Laboratory Considerations

Bisphosphonate therapy requires baseline and periodic assessment of renal function, calcium homeostasis, and bone turnover.

Before Initiation

Check serum 25-hydroxyvitamin D, calcium, and estimated GFR. Oral bisphosphonates are not recommended when eGFR is <30 to 35 mL/min. Zoledronic acid is contraindicated at eGFR <35 mL/min [3]. Correct vitamin D deficiency (target 30 ng/mL or above) before starting therapy. Hypocalcemia must be resolved before the first dose.

During Therapy

The 2024 AACE Osteoporosis Clinical Practice Guidelines recommend measuring a bone turnover marker (C-telopeptide [CTX] or procollagen type 1 N-terminal propeptide [P1NP]) at baseline and 3 to 6 months after initiation to confirm therapeutic response [15]. CTX suppression below 150 pg/mL typically confirms adequate osteoclast inhibition. Repeat DXA at 2 years. Earlier repeat (12 months) is reasonable after a fracture or when adherence is uncertain.

Drug Holiday Decisions

The 2024 AACE guideline recommends reassessing after 3 to 5 years of oral bisphosphonate therapy or 3 years of IV zoledronic acid [15]. Patients at moderate fracture risk may be considered for a holiday. Patients at high risk (T-score still <-2.5, history of vertebral fracture, high FRAX score) should generally continue or transition to an anabolic agent. During a holiday, repeat CTX or P1NP annually. A rising turnover marker (CTX above 300 pg/mL) or a new fracture signals the need to restart.

The Endocrine Society's 2020 guideline offers a similar recommendation: "Reassess fracture risk after 5 years of oral bisphosphonate therapy. For those at high risk of fracture, continuation of therapy or switching to an alternative agent is recommended" [8].

Drug Interactions and Special Populations

Oral Absorption Interactions

Calcium, iron, magnesium, aluminum-containing antacids, and proton pump inhibitors (when taken simultaneously) all reduce bisphosphonate absorption. Separate oral bisphosphonates from all other medications by at least 30 minutes. This is not optional. It is a hard pharmacokinetic requirement.

Renal Impairment

Bisphosphonates are renally cleared without hepatic metabolism. Dose adjustment data are limited below eGFR 30 mL/min. In practice, patients with CKD stage 4 to 5 are transitioned to denosumab, which does not require renal dose adjustment [8].

Pregnancy and Pediatrics

Bisphosphonates are category X equivalents (FDA no longer uses letter categories, but the risk is clear). Animal studies show fetal skeletal abnormalities. Given the long skeletal half-life, bisphosphonates should be avoided in women of childbearing potential unless no alternative exists. Pediatric use is limited to osteogenesis imperfecta, where IV pamidronate has the most supporting evidence [16].

Positioning in the 2024 Treatment Algorithm

Bisphosphonates remain the recommended first-line therapy for most patients with osteoporosis who are at moderate fracture risk, according to both the 2024 AACE and 2020 Endocrine Society guidelines [8][15].

When to Start With an Anabolic Agent Instead

For patients at very high fracture risk (recent vertebral fracture, T-score <-3.0, high FRAX probability), anabolic-first sequencing with romosozumab or teriparatide followed by an antiresorptive is now preferred. The ARCH trial (N=4,093) demonstrated that romosozumab for 12 months followed by alendronate reduced vertebral fracture risk by 48% compared to alendronate alone [17].

Sequential and Combination Strategies

A consistent principle across guidelines: never follow an anabolic agent with a drug holiday. The bone density gains from teriparatide or romosozumab are rapidly lost without consolidation therapy. An oral or IV bisphosphonate is the standard consolidation agent after completing 12 to 24 months of anabolic treatment [15].

Switching to Denosumab

When bisphosphonate intolerance (GI toxicity, renal impairment) limits use, denosumab 60 mg SC every 6 months is the primary alternative antiresorptive. A critical clinical note: discontinuing denosumab without transitioning to a bisphosphonate triggers a rebound increase in bone turnover and can cause multiple vertebral fractures within 12 months [18]. This rebound phenomenon does not occur with bisphosphonate discontinuation because of the long skeletal half-life.

Cost and Access Considerations

Generic alendronate 70 mg weekly is among the least expensive osteoporosis treatments available, often under $4/month through discount pharmacy programs. Risedronate generics are moderately priced at $15 to $40/month. Zoledronic acid 5 mg IV (generic) costs approximately $200 to $500 per infusion before insurance, but the once-yearly schedule reduces total annual cost and clinic visits. Ibandronate IV is largely being replaced by zoledronic acid due to the latter's superior fracture data and equivalent convenience.

Medicare Part B covers IV zoledronic acid administered in the physician office setting. Oral bisphosphonates are covered under Part D. Prior authorization is rarely required for generic oral agents. The cost-effectiveness of alendronate has been demonstrated at a willingness-to-pay threshold of $60,000 per QALY in women aged 65 and older with osteoporosis [19].